logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Conference Material
|
Poster

Effectiveness of a community-based intervention program in reducing childhood obesity: A prospective cohort study

Karki S, Rijal S, Vaidya M, Chaulugain RH
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024
Journal Article
|
Research

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Schilling WHK, Mukaka M, Callery JJ, Llewelyn MJ, Cruz CV,  et al.
2024-09-12 • PLOS Medicine
2024-09-12 • PLOS Medicine

BACKGROUND

Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety an...

Journal Article
|
Research

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...
Journal Article
|
Research

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS,  et al.
2018-10-22 • PLOS Neglected Tropical Diseases
2018-10-22 • PLOS Neglected Tropical Diseases
BACKGROUND
In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...
Journal Article
|
Research

Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data

Cloots K, Burza S, Malaviya P, Hasker E, Kansal S,  et al.
2020-01-29 • PLOS Neglected Tropical Diseases
2020-01-29 • PLOS Neglected Tropical Diseases
BACKGROUND
Bangladesh, India, and Nepal aim for the elimination of Visceral Leishmaniasis (VL), a systemic parasitic infectious disease, as a public health problem by 2020. For decad...
Journal Article
|
Research

Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India

Goyal V, Burza S, Pandey K, Singh SN, Singh RS,  et al.
2019-09-26 • PLOS Neglected Tropical Diseases
2019-09-26 • PLOS Neglected Tropical Diseases
BACKGROUND:
An earlier open label, prospective, non-randomized, non-comparative, multi-centric study conducted within public health facilities in Bihar, India (CTRI/2012/08/002891) ...
Journal Article
|
Review

Clinical Research in Neglected Tropical Diseases: The Challenge of Implementing Good Clinical (Laboratory) Practices

Ravinetto R, Alirol E, Mahendradhata Y, Rijal S, Lutumba P,  et al.
2016-11-03 • PLOS Neglected Tropical Diseases
2016-11-03 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Who Is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia

Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Angeles Lima M,  et al.
2011-04-05 • American Journal of Tropical Medicine and Hygiene
2011-04-05 • American Journal of Tropical Medicine and Hygiene
Drug-dosing recommendations for visceral leishmaniasis (VL) treatment are based on the patients' weight or age. A current lack of demographic and anthropometric data on patients hinders ...